Abstract: Provided herein are methods for alleviating symptoms in a subject having a neurodegenerative disorder, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) or to its Plexin-B1 or Plexin-B2 receptors.
Type:
Grant
Filed:
July 2, 2019
Date of Patent:
October 13, 2020
Assignee:
Vaccinex, Inc.
Inventors:
Ernest S. Smith, Maurice Zauderer, William J. Bowers, Alan Jonason
Abstract: Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising the p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB.
Type:
Grant
Filed:
May 8, 2018
Date of Patent:
September 15, 2020
Assignee:
Bioasis Technologies, Inc.
Inventors:
Timothy Z. Vitalis, Reinhard Gabathuler
Abstract: Provided herein are methods and uses involving antibodies that specifically bind to a KIT receptor tyrosine kinase for managing, treating, or preventing an eosinophil or mast cell related disorder and/or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).
Abstract: Described herein are methods, systems and compositions for the diagnosis, prognosis and treatment of dementia and Alzheimer's disease. Also described are methods, systems and compositions to distinguish between Alzheimer's disease and Parkinson's disease. In various embodiments levels of PACAP and/or SIRT3 are analyzed for the diagnosis, prognosis and treatment of dementia and Alzheimer's disease.
Abstract: The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease.
Type:
Grant
Filed:
February 21, 2019
Date of Patent:
September 15, 2020
Assignee:
The Regents of the University of California
Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.
Type:
Grant
Filed:
November 20, 2017
Date of Patent:
September 8, 2020
Assignees:
ALDERBIO HOLDINGS LLC, THE UNIVERSITY OF IOWA RESEARCH FOUNDATION
Inventors:
Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian R. Kovacevich, John Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez
Abstract: The present invention relates to a method of identifying a compound that binds to or modulates the activity of one or more polypeptides encoding one or more receptors that are involved in the detection and perception of fatty acids.
Type:
Grant
Filed:
August 8, 2019
Date of Patent:
September 8, 2020
Assignee:
MARS, INCORPORATED
Inventors:
Scott Joseph McGrane, Andrew John Taylor, Matthew Ronald Gibbs, Richard Masten Fine, Boris Klebansky
Abstract: NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone, a) in combination with other drugs used for treating dementia, b) in combination with drugs that stabilize or increase blood plasma glucose levels, or with both a) and b). Pharmaceutical compositions, dosage forms, and methods for using the same are disclosed, which include NSC antagonists, NSC antagonists combined with dementia drugs, NSC antagonists combined with glucose-level stabilizing or enhancing drugs, or combinations of these. Dosage forms may be designed to provide stable plasma levels for extended periods of time.
Abstract: Disclosed is a protein comprising no more than three human autoantigenic proteins, wherein a first human autoantigenic protein comprises a truncated myelin oligodendrocyte glycoprotein (MOG) amino acid sequence, a second human autoantigenic protein comprises a myelin basic protein (MBP) amino acid sequence, and a third human autoantigenic protein comprises a truncated proteolipid protein (PLP) amino acid sequence. Also disclosed are related nucleic acids, pharmaceutical compositions, methods of treating a demyelinating disease, and methods of producing the proteins.
Type:
Grant
Filed:
March 9, 2016
Date of Patent:
September 1, 2020
Assignee:
The United States of America, as represented by the Secretary, Department of Health & Human Services
Inventors:
Michael J. Lenardo, Jian Li, Lixin Zheng, Jae W. Lee, Wei Lu
Abstract: The present disclosure relates to methods and compositions for detecting mitochondrial dysfunction. In particular, the disclosure relates to reporter molecules that are cleavable by the zinc metalloprotease Metalloendopeptidase OMA1 (OMA1). In each embodiment, the reporter molecules of the invention are particularly useful for drug discovery and detection of diseases associated with mitochondrial dysfunction.
Abstract: The present invention encompasses compositions and methods for regulating the kynurenine to tryptophan ratio, NAD+ level and CD16 expression for the treatment diseases.
Type:
Grant
Filed:
December 2, 2016
Date of Patent:
July 28, 2020
Assignee:
Temple University—Of The Commonwealth System of Higher Education
Inventors:
Jay F. Rappaport, Xuebin Qin, Stephani Velasquez
Abstract: The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s). Also described herein are compositions and methods of use thereof for treating multiple sclerosis.
Type:
Grant
Filed:
July 3, 2018
Date of Patent:
July 7, 2020
Assignee:
UNIVERSITY OF MIAMI
Inventors:
Robert W. Keane, W. Dalton Dietrich, Juan Pablo De Rivero Vaccari, Helen M. Bramlett, Roberta Brambilla
Abstract: The invention relates to novel peptides, polypeptides or proteins which specifically bind to cells of the brain and/or the spinal cord. The peptides, polypeptides or proteins can be part of a viral capsid, and they can be used for guiding a recombinant viral vector selectively to the brain and/or spinal cord after systemic administration to a subject, where it provides for a tissue-specific expression of one or more transgenes. The invention therefore also relates to a recombinant viral vector, preferably an AAV vector, comprising a capsid containing at least one of the peptides, polypeptides or proteins of the invention and at least one transgene which is packaged within the capsid. The viral vector is particularly suitable for the therapeutic treatment of a disease or functional disorder of the brain and/or the spinal cord. The invention further relates to cells and pharmaceutical compositions comprising the viral vector of the invention.
Type:
Grant
Filed:
January 31, 2019
Date of Patent:
June 30, 2020
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Jakob Körbelin, Stefan Michelfelder, Martin Trepel
Abstract: The invention provides a series of peptides with N-methyl-D-aspartate (NMDA) receptor modulating activity. Specifically it contains two synthetic peptides acting as ion inflow antagonists through the NMDA receptor with specificity GluN2B and GluN2A NMDA receptor subunits and a peptide having agonist activity regarding the NMDA receptor in rat hippocampal neuron cultures.
Type:
Grant
Filed:
December 22, 2016
Date of Patent:
June 23, 2020
Assignee:
Universidad Nacional de Colombia
Inventors:
Edgar Antonio Reyes Montaño, Edwin Alfredo Reyes Guzmán, Nohora Angélica Vega Castro
Abstract: The present invention provides methods and compositions for treating atherosclerosis in a subject comprising the use of therapeutic compounds to reduce Reelin in the circulation of the subject, thereby reducing the adhesion of leukocytes to the vascular wall. The invention also provides methods and compositions for reducing leukocyte adhesion to the vascular wall in a subject.
Type:
Grant
Filed:
September 23, 2016
Date of Patent:
June 16, 2020
Assignee:
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Inventors:
Joachim Herz, Yinyuan Ding, Xunde Xian, Linzhang Huang, Chieko Mineo, Philip Shaul, Laurent Calvier
Abstract: Provided herein are GPCR-based chemical biosensors that can have a sensing unit, a processing unit, and a response unit that can be used to detect a chemical of interest. Also provided herein are methods of making and using the GPCR-based chemical biosensors.
Type:
Grant
Filed:
November 6, 2017
Date of Patent:
June 16, 2020
Assignee:
Georgia Tech Research Corporation
Inventors:
Pamela Peralta-Yahya, Kuntal Mukherjee, Souryadeep Bhattacharyya, Stephen Sarria
Abstract: Embodiments described herein relate to restorative solutions for segmental peripheral nerve (PN) defects using allografted PNs for stimulating PN repair. More specifically, embodiments described herein provide for localized immunosuppression (LIS) surrounding PN allografts as an alternative to systemically suppressing a patient's entire immune system. Methods include localized release of immunosuppressive (ISV) agents are contemplated in one embodiment. Methods also include localized application of immunosuppressive (ISV) regulatory T-cells (Tregs) in other embodiments. Hydrogel carrier materials for delivery of ISV agents and are also described herein.
Abstract: A peptide which has a neuroprotective action, a neuroprotective drug and neuropathic treatment containing the peptide, and a preventive or alleviative pharmaceutical composition. The peptide comprises proline-rich protein 4 having the sequence of SEQ ID NO:1 or a partial sequence thereof, or a modified sequence thereof, which has a neuroprotective action.
Abstract: Disclosed herein are methods and compositions for identifying and/or treating subjects having or likely to have amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). Antibodies specific for one or more di-amino acid repeat-containing proteins are also provided herein.
Type:
Grant
Filed:
March 25, 2019
Date of Patent:
May 26, 2020
Assignee:
University of Florida Research Foundation, Incorporated